JPWO2021243002A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021243002A5 JPWO2021243002A5 JP2022573247A JP2022573247A JPWO2021243002A5 JP WO2021243002 A5 JPWO2021243002 A5 JP WO2021243002A5 JP 2022573247 A JP2022573247 A JP 2022573247A JP 2022573247 A JP2022573247 A JP 2022573247A JP WO2021243002 A5 JPWO2021243002 A5 JP WO2021243002A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ldl
- subject
- weeks
- hefh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032451P | 2020-05-29 | 2020-05-29 | |
| US63/032,451 | 2020-05-29 | ||
| PCT/US2021/034489 WO2021243002A1 (en) | 2020-05-29 | 2021-05-27 | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023527542A JP2023527542A (ja) | 2023-06-29 |
| JPWO2021243002A5 true JPWO2021243002A5 (https=) | 2024-06-03 |
| JP2023527542A5 JP2023527542A5 (https=) | 2024-06-03 |
Family
ID=78722769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573247A Pending JP2023527542A (ja) | 2020-05-29 | 2021-05-27 | コレステロール関連障害を治療するためのｐｃｓｋ９阻害剤及びその使用の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230235085A1 (https=) |
| EP (1) | EP4157887A4 (https=) |
| JP (1) | JP2023527542A (https=) |
| CN (1) | CN115916838A (https=) |
| AR (1) | AR122180A1 (https=) |
| AU (1) | AU2021281256A1 (https=) |
| CA (1) | CA3179316A1 (https=) |
| IL (1) | IL298375A (https=) |
| JO (1) | JOP20220322A1 (https=) |
| TW (1) | TW202210524A (https=) |
| WO (1) | WO2021243002A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| CN121693519A (zh) | 2023-08-14 | 2026-03-17 | 信立泰(成都)生物技术有限公司 | Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法 |
| WO2025265012A1 (en) * | 2024-06-21 | 2025-12-26 | Amgen Inc. | Compositions comprising anti-pcsk9 antbodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009033743A1 (en) * | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| PL3169353T3 (pl) * | 2014-07-16 | 2020-06-01 | Sanofi Biotechnology | SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH) |
-
2021
- 2021-05-27 CA CA3179316A patent/CA3179316A1/en active Pending
- 2021-05-27 CN CN202180039317.4A patent/CN115916838A/zh active Pending
- 2021-05-27 AR ARP210101427A patent/AR122180A1/es unknown
- 2021-05-27 JP JP2022573247A patent/JP2023527542A/ja active Pending
- 2021-05-27 WO PCT/US2021/034489 patent/WO2021243002A1/en not_active Ceased
- 2021-05-27 IL IL298375A patent/IL298375A/en unknown
- 2021-05-27 EP EP21812361.0A patent/EP4157887A4/en active Pending
- 2021-05-27 US US17/999,373 patent/US20230235085A1/en active Pending
- 2021-05-27 AU AU2021281256A patent/AU2021281256A1/en active Pending
- 2021-05-28 TW TW110119435A patent/TW202210524A/zh unknown
-
2022
- 2022-11-27 JO JOJO/P/2022/0322A patent/JOP20220322A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saunders et al. | Triple therapy in early active rheumatoid arthritis: a randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategies | |
| JP2020002171A5 (https=) | ||
| CN116261463A (zh) | 治疗痛风的方法 | |
| AU2015315628A1 (en) | Use of reslizumab to treat moderate to severe eosinophilic asthma | |
| JP2021515770A5 (https=) | ||
| US20250075007A1 (en) | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells | |
| CN115052628A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| JP2021532176A5 (https=) | ||
| CN115702023A (zh) | 化脓性汗腺炎的治疗 | |
| JPWO2021243002A5 (https=) | ||
| JP2025106329A (ja) | ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法 | |
| TWI850365B (zh) | 治療克隆氏症(crohn's disease)的方法 | |
| AU2017355613A1 (en) | Treatment regimens | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| JPWO2020186132A5 (https=) | ||
| JPWO2019171252A5 (https=) | ||
| Konstantinou et al. | Paradoxical worsening of chronic spontaneous Urticaria following Omalizumab administration: the missing link | |
| JP2024517796A (ja) | 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療 | |
| JP2023521909A (ja) | 呼吸器疾患の治療 | |
| JP2025537966A (ja) | 潰瘍性大腸炎を治療する方法 | |
| WO2025238121A1 (en) | Anti-il-5 antibody in the treatment of asthma | |
| JPWO2022074603A5 (https=) | ||
| US20220306749A1 (en) | Use of an Anti-P-selectin Antibody | |
| JP2026503503A (ja) | 免疫介在性壊死性ミオパチーの治療及び予防のための抗ｃｄ１９結合剤 | |
| CN114746444A (zh) | 使用白介素-17(il-17)拮抗剂治疗扁平苔藓的方法 |